Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for UNITED THERAPEUTICS (UTHR) over the last 9 years, with Dec 2024 value amounting to $48.5 million.

  • UNITED THERAPEUTICS's Shares Outstanding (Diluted Average) fell 0.82% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 0.82%. This contributed to the annual value of $48.5 million for FY2024, which is 2.41% down from last year.
  • Latest data reveals that UNITED THERAPEUTICS reported Shares Outstanding (Diluted Average) of $48.5 million as of FY2024, which was down 2.41% from $49.7 million recorded in FY2023.
  • In the past 5 years, UNITED THERAPEUTICS's Shares Outstanding (Diluted Average) ranged from a high of $49.7 million in FY2023 and a low of $44.6 million during FY2020.
  • Over the past 3 years, UNITED THERAPEUTICS's median Shares Outstanding (Diluted Average) value was $48.5 million (recorded in 2024), while the average stood at $48.9 million.
  • As far as peak fluctuations go, UNITED THERAPEUTICS's Shares Outstanding (Diluted Average) climbed by 6.05% in 2021, and later decreased by 2.41% in 2024.
  • Yearly analysis of 5 years shows UNITED THERAPEUTICS's Shares Outstanding (Diluted Average) stood at $44.6 million in 2020, then grew by 6.05% to $47.3 million in 2021, then climbed by 2.54% to $48.5 million in 2022, then increased by 2.47% to $49.7 million in 2023, then dropped by 2.41% to $48.5 million in 2024.